Black Swan Analysis Epiomic™ Epidemiology Forecast Report on Addison’s Disease in 22 Major Markets
Addison's disease (AD) is a chronic and rare endocrinal disorder, caused by destruction of the adrenal cortex which leads to the reduced production of glucocorticoids, mineralocorticoids and adrenal androgens. Chronic adrenal insufficiency and hypersecretion of ACTH is representative of the basic clinical signs and symptoms. AD can be part of the autoimmune polyglandular syndrome (PAS) (type 1 and 2), or it may present as an isolated disorder. PAS usually also affects other endocrine glands including the thyroid, pancreatic beta cells and stomach cells that allow absorption of vitamin B12 (producing pernicious anaemia).
This report provides the current prevalent population for AD across 22 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Norway, Sweden, Iceland, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, AD patients grouped by disease classification and comorbidities have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities of AD include:
• Autoimmune thyroiditis (AT)
• Type 1 diabetes (T1D)
• Anaemia
• Vitiligo
• Chronic fatigue
• Premature ovarian failure
• Hypopigmentation
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Ability to quantify patient populations in global AD market to target the development of future products, pricing strategies and launch plans.
• Further insight into the prevalence of the subdivided types of AD and identification of patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Better understanding of the impact of specific co-morbid conditions on the prevalent population of AD patients.
• Identification of AD patient sub-populations that require treatment.
• Better understanding of the specific markets that have the largest number of AD patients.
Epiomic Epidemiology Series: Addison’s Disease Forecast in 22 Major Markets 2018–2028
CONTENTS
• LIST OF TABLES AND FIGURES
• INTRODUCTION
• CAUSE OF THE DISEASE
• RISK FACTORS & PREVENTION
• DIAGNOSIS OF THE DISEASE
• VARIATION BY GEOGRAPHY/ETHNICITY
• DISEASE PROGNOSIS & CLINICAL COURSE
• KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
• METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
• TOP-LINE PREVALENCE FOR ADDISON’S DISEASE
• FEATURES OF ADDISON’S DISEASE PATIENTS
• COMORBIDITIES OF ADDISON’S DISEASE PATIENTS
• ABBREVIATIONS USED IN THE REPORT
• OTHER BLACK SWAN SERVICES & SOLUTIONS
• REPORTS & PUBLICATIONS
• ONLINE EPIDEMIOLOGY DATABASES
• ONLINE PHARMACEUTICAL PRICING DATABASE
• REFERENCES
• APPENDIX
LIST OF TABLES AND FIGURES
• Table 1. Development stages of AAD
• Table 2. Prevalence of AD, total (000s)
• Table 3. Prevalence of AD, males (000s)
• Table 4. Prevalence of AD, females (000s)
• Table 5. Patients with AD by classification, total (000s)
• Table 6. Patients with AD by number of concomitant conditions, total (000s)
• Table 7. Addison's disease patients with autoimmune thyroid disease, total (000s)
• Table 8. Addison's disease patients with type 1 diabetes, total (000s)
• Table 9. Addison's disease patients with anaemia, total (000s)
• Table 10. Addison's disease patients with vitiligo, total (000s)
• Table 11. Addison's disease patients with chronic fatigue, total (000s)
• Table 12. Addison's disease patients with premature ovarian failure, females (000s)
• Table 13. Abbreviations and acronyms used in the report
• Table 14. USA prevalence of AD by 5-yr age cohort, males (000s)
• Table 15. USA prevalence of AD by 5-yr age cohort, females (000s)
• Table 16. Canada prevalence of AD by 5-yr age cohort, males (000s)
• Table 17. Canada prevalence of AD by 5-yr age cohort, females (000s)
• Table 18. France prevalence of AD by 5-yr age cohort, males (000s)
• Table 19. France prevalence of AD by 5-yr age cohort, females (000s)
• Table 20. Germany prevalence of AD by 5-yr age cohort, males (000s)
• Table 21. Germany prevalence of AD by 5-yr age cohort, females (000s)
• Table 22. Italy prevalence of AD by 5-yr age cohort, males (000s)
• Table 23. Italy prevalence of AD by 5-yr age cohort, females (000s)
• Table 24. Spain prevalence of AD by 5-yr age cohort, males (000s)
• Table 25. Spain prevalence of AD by 5-yr age cohort, females (000s)
• Table 26. UK prevalence of AD by 5-yr age cohort, males (000s)
• Table 27. UK prevalence of AD by 5-yr age cohort, females (000s)
• Table 28. Poland prevalence of AD by 5-yr age cohort, males (000s)
• Table 29. Poland prevalence of AD by 5-yr age cohort, females (000s)
• Table 30. Netherlands prevalence of AD by 5-yr age cohort, males (000s)
• Table 31. Netherlands prevalence of AD by 5-yr age cohort, females (000s)
• Table 32. Norway prevalence of AD by 5-yr age cohort, males (000s)
• Table 33. Norway prevalence of AD by 5-yr age cohort, females (000s)
• Table 34. Sweden prevalence of AD by 5-yr age cohort, males (000s)
• Table 35. Sweden prevalence of AD by 5-yr age cohort, females (000s)
• Table 36. Iceland prevalence of AD by 5-yr age cohort, males (000s)
• Table 37. Iceland prevalence of AD by 5-yr age cohort, females (000s)
• Table 38. Russia prevalence of AD by 5-yr age cohort, males (000s)
• Table 39. Russia prevalence of AD by 5-yr age cohort, females (000s)
• Table 40. Turkey prevalence of AD by 5-yr age cohort, males (000s)
• Table 41. Turkey prevalence of AD by 5-yr age cohort, females (000s)
• Table 42. Japan prevalence of AD by 5-yr age cohort, males (000s)
• Table 43. Japan prevalence of AD by 5-yr age cohort, females (000s)
• Table 44. China prevalence of AD by 5-yr age cohort, males (000s)
• Table 45. China prevalence of AD by 5-yr age cohort, females (000s)
• Table 46. South Korea prevalence of AD by 5-yr age cohort, males (000s)
• Table 47. South Korea prevalence of AD by 5-yr age cohort, females (000s)
• Table 48. India prevalence of AD by 5-yr age cohort, males (000s)
• Table 49. India prevalence of AD by 5-yr age cohort, females (000s)
• Table 50. Australia prevalence of AD by 5-yr age cohort, males (000s)
• Table 51. Australia prevalence of AD by 5-yr age cohort, females (000s)
• Table 52. Brazil prevalence of AD by 5-yr age cohort, males (000s)
• Table 53. Brazil prevalence of AD by 5-yr age cohort, females (000s)
• Table 54. Mexico prevalence of AD by 5-yr age cohort, males (000s)
• Table 55. Mexico prevalence of AD by 5-yr age cohort, females (000s)
• Table 56. Argentina prevalence of AD by 5-yr age cohort, males (000s)
• Table 57. Argentina prevalence of AD by 5-yr age cohort, females (000s)
